Oxford BioMedica could pocket $100m on Novartis CAR-T cell success
Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.
Archives for August 30, 2017
‘A new frontier:’ US FDA approves Novartis’ $475,000 CAR-T cell cancer therapy
Kymriah (tisagenlecleucel), made at the former-Dendreon site in New Jersey, has become the first gene modified cell therapy to be approved in the US.